ESR1 and breast carcinoma: Our data support the further investigation of OAds in combination with other CDK4/6 inhibitors in vivo to determine the potential of this strategy to prolong the response time and overcome resistance to palbociclib, which will ultimately impact the survival of ER+ breast cancer patients.